Skip to main content

ご注意

現在、日本語に対応しているのは、Luminex LTGのセクションとLuminex LTGのサービス&サポートページのみです。

Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese.

Results

Select period of competence

9M 2023 Results Presentation

Third Quarter results confirm guidance for Fiscal Year 2023

H1 2023 Results Presentation

Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed

Q1 2023 Results Presentation

Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023

FY 2022 Results Presentation

REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE

9M 2022 Results Presentation

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards

H1 2022 Results Presentation

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards

Q1 2022 Results Presentation

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards

FY 2021 Results Presentation

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021

9M 2021 Results Presentation

DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021

H1 2021 Results Presentation

DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex

Q1 2021 Results Presentation

DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021

FY 2020 Results Presentation

Revenues, Profitability and Cash Flow Generation hit record highs in 2020

9M 2020 Results Presentation

North America growth drives up revenues and profitability in the first 9 months of 2020

H1 2020 Results Presentation

North America business growth drives Group revenues and profitability in H1 2020

Q1 2020 Results Presentation

DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic

FY 2019 Results Presentation

DiaSorin - Cash flow generation and net profit hit record highs in 2019

9M 2019 Results Presentation

Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019

H1 2019 Results Presentation

DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability.

Q1 2019 Results Presentation

DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019

FY 2018 Results Presentation

Growth in revenues, profitability and net profit in 2018

9M 2018 Results Presentation

DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018

H1 2018 Results Presentation

The Board of Directors approves the results for the first half of 2018

Q1 2018 Results Presentation

The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018

FY 2017 Results Presentation

DiaSorin: FY 2017 Results

FY 2016 Results Presentation

The Board of Directors approves the results for FY'16

FY 2015 Results Presentation

The Board of Directors approves the results for FY'15

FY 2014 Results Presentation

The Board of Directors approves the results for FY'14